MCV4

BIOLOGICAL6 trials

Sponsors

CanSino Biologics Inc.

Conditions

Diphtheria, Tetanus and Acellular PertussisEpidemic MeningitisHaemophilus Influenzae Type B InfectionMeningococcal Meningitis

Phase 1

Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine

RecruitingNCT07203755

CanSino Biologics Inc.Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection

Start: 2025-12-19End: 2029-02-28Target: 260Updated: 2025-12-31

Phase 3

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population

CompletedNCT06011200

CanSino Biologics Inc.Epidemic Meningitis

Start: 2023-09-16End: 2024-05-11Updated: 2025-07-03

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

Active, not recruitingNCT06226714

CanSino Biologics Inc.Meningococcal Meningitis

Start: 2024-03-01End: 2025-08-31Updated: 2025-07-29

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds

CompletedNCT06700148

CanSino Biologics Inc.Meningococcal Meningitis

Start: 2024-12-14End: 2025-07-16Updated: 2026-08-06

Phase 4

Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Active, not recruitingNCT05935176

CanSino Biologics Inc.Epidemic Meningitis

Start: 2023-09-20End: 2026-07-15Updated: 2026-03-04

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

CompletedNCT06389513

CanSino Biologics Inc.Epidemic Meningitis

Start: 2024-06-12End: 2026-05-01Updated: 2026-08-13